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Abstract
 
A rodent model of sepsis was used to establish the relationship between caspase inhibition and
inhibition of apoptotic cell death in vivo. In this model, thymocyte cell death was blocked by
Bcl-2 transgene, indicating that apoptosis was predominantly dependent on the mitochondrial
pathway that culminates in caspase-3 activation. Caspase inhibitors, including the selective
caspase-3 inhibitor M867, were able to block apoptotic manifestations both in vitro and in
vivo but with strikingly different efficacy for different cell death markers. Inhibition of DNA
fragmentation required substantially higher levels of caspase-3 attenuation than that required for
blockade of other apoptotic events such as spectrin proteolysis and phosphatidylserine externaliza-
tion. These data indicate a direct relationship between caspase inhibition and some apoptotic
manifestations but that small quantities of uninhibited caspase-3 suffice to initiate genomic
DNA breakdown, presumably through the escape of catalytic quantities of caspase-activated
DNase. These findings suggest that putative caspase-independent apoptosis may be overestimated
in some systems since blockade of spectrin proteolysis and other cell death markers does not accu-
rately reflect the high degrees of caspase-3 inhibition needed to prevent DNA fragmentation.
Furthermore, this requirement presents substantial therapeutic challenges owing to the need for
persistent and complete caspase blockade.
Key words: peritonitis • caspase-3 • spectrin • ICAD • thymocytes
 
Introduction
 
Apoptosis is an evolutionary conserved process in which
the caspase family of cysteine proteases plays an essential
role. To date, 14 caspases have been identified in mammals,
with some functioning in cytokine processing and inflamma-
tion and at least 8 others contributing to programmed cell
death. The apoptotic caspases can be further divided into
the initiator caspase group, which includes caspase-2, -8, -9,
and -10, and the effector caspase group, to which caspase-3,
-6, and -7 belong (for reviews see references 1, 2). Depletion
experiments in cell-free extracts indicate that caspase-3 is
the principal effector caspase (3). On the other hand,
knockout studies suggest a partial redundancy in the role of
caspase-3 and other caspases such as caspase-7 (4). In addition
to cleaving themselves, active caspases proteolyse a set of
protein substrates with the loosely conserved recognition
sequence X-E-X-D. Cleavage occurs exclusively after the
aspartic acid residue (1, 2). Many caspase substrates play key
roles in cell function and architecture, and alteration of
their normal function by caspase-mediated cleavage is
thought to contribute to the characteristic morphological
features of apoptotic cells (5).
A large number of pathologies exhibit either too much
or too little apoptosis, and it is of considerable interest to
develop agents that will modulate programmed cell death
in patients (6). A potential target for antiapoptotic agents
is the microbial-elicited systemic inflammatory response
known as sepsis. This disease is fatal in 30–40% of cases and
is the highest cause of mortality in intensive care units (7).
Recent studies uncovered a depletion of B and T cells in
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the lymphoid organs and the presence of apoptotic markers
in lymphocytes and intestinal epithelial cells of septic pa-
tients (8, 9). Loss of B and T cells was observed in the
spleen and thymus of rodents in which sepsis was induced
by cecal ligation and perforation (CLP; references 10, 11).
Overexpression of breakpoint cluster (Bcl)-2 in B, T, or
intestinal epithelial cells reduced CLP- or pneumonia-
induced murine sepsis and increased survival (12–15), as did
the administration of caspase inhibitors (16). Based on these
studies, blockade of apoptosis using caspase inhibitors con-
stitutes a potential treatment. Development of such inhibi-
tors will require an accurate quantitation of caspase-depen-
dent events during sepsis and the percentage of active
caspases that must be inhibited for efficacy in vivo. To this
end, we examined various manifestations of apoptosis dur-
ing CLP-induced sepsis in both rats and mice. We found
that monitoring of DNA fragmentation and 
 
 
 
II-spectrin
cleavage, as opposed to phosphatidylserine (PS) exposure,
provides a more accurate measurement of apoptosis-related
events during sepsis. Surprisingly, studies with both cas-
pase-3–specific and polycaspase inhibitors reveal different
potencies at curbing these apoptotic manifestations, both in
vivo and in cell culture, illustrating the need to follow sev-
eral cell death markers. From these findings, we conclude
that a high degree of fractional caspase inhibition is neces-
sary to completely block apoptotic cell death. This estab-
lishes, in an animal model of inappropriate apoptosis (CLP-
induced sepsis), the required levels of caspase inhibitors
needed for improved survival and the potential challenges
that face the use of caspase inhibitors in human diseases.
 
Materials and Methods
 
Animals.
 
Female Sprague-Dawley rats (250–300 g; Charles
River) and C57Bl/6-TgN(BCL-2)25 Wehi mice, heterozygous
and WT siblings (20–25 g; stock no. 2320; Jackson Laboratories)
were housed in a 12-h light–dark cycle with free access to food
and water. All procedures were performed under appropriate An-
imal Care Committee approval in strict accordance to Merck and
Co. animal care policies.
 
Surgical Procedures.
 
Animals were anesthetized with 2.5% iso-
flurane in oxygen, and body temperature was maintained by use
of a thermoregulated heated blanket.
CLP was performed as follows. A midline incision was made in
the abdominal wall of the animal and the cecum exteriorized. The
cecum was ligated with a nylon (4–0) suture proximal to the ileo-
cecal valve. In mice, perforation of the cecum was done using a
23-gauge needle passed through the distal portion of the cecum.
Femoral vein cannulation of rats was performed by a small incision
in the inguinal region, and the femoral vein was isolated. A Sili-
cone catheter (0.02
 
 
 
inches 
 
  
 
0.037 inches; Lomir) connected to a
polyurethane catheter (PU-C30, 3 French, 80 cm; Instech So-
lomon) was inserted into the vena cava, exteriorized at the nape of
the neck, and clamped for the duration of the surgery. Cannula-
tion was immediately followed by CLP using a 20-gauge cannula
(Abbott Ireland) passed through and through the distal portion of
the exteriorized cecum. Braided silk (size 0) was threaded through
the cannula and secured in place to allow leakage of the cecal con-
tent into the peritoneum. Sham-operated animals had the cecum
exteriorized but no ligation or puncture of the cecum. The ab-
dominal wall was sutured with polydioxane suture (4–0) and the
skin sutured with surgical glue (mice) or clips (rats). Immediately
after surgery, all animals received 1 c.c. of 0.9% saline administered
by subcutaneous injection. A 2 ml/kg bolus of vehicle or com-
pound (M867) was administered via the i.v. catheter, which was
then connected to a Medfusion 2010
 
i
 
 Syringe pump (Medex Inc.)
at a delivery rate of 2 ml/h/kg for 24 h.
 
Thymic Protein Extract Preparation.
 
Thymi from rats or mice
were recovered 24 h postsurgery and processed within 20 min of
their removal. A cell suspension was obtained by grinding tissues
in 50 
 
 
 
m Medicon and Medimachine (Dako) with 2 ml of ice
cold thymocyte isolation buffer (PBS, 2 mM glucose, 2 mM 
 
l
 
-glu-
tamine, 1% FBS) with 2 
 
 
 
 15-s pulses. Cell suspensions were fil-
tered through 50 
 
 
 
m nylon mesh filters (Becton Dickinson). Red
blood cells were eliminated by a 10-min incubation in hypotonic
buffer (17 mM Tris-Cl, pH 7.5, 140 mM NH
 
4
 
Cl). For some ex-
periments, thymocytes were put in culture for 24 h at a density of
10 
 
 
 
 10
 
6
 
 cells/ml in CytoSF4 (Kemp Technologies) supple-
mented with 
 
l
 
-glutamine and antibiotics. Thymi fragments were
lysed in cell lysis buffer (50 mM Tris-Cl, pH 7.5, 2 mM EDTA,
1% NP-40) supplemented with complete protease inhibitor
(Roche), caspase inhibitor (M029), and calpain inhibitor (M638).
Protein in the soluble fraction was quantitated with the BCA
protein detection kit (Pierce Chemical Co.).
 
Enzyme-linked Immunosorbant Assays.
 
DNA-histone sandwich
ELISA was performed using the Cell Death Detection ELISA kit
(Roche) according to the manufacturer’s specifications. All assays
were performed on protein extracts that had not been frozen
since freeze-thawing alters results. 
 
 
 
II-spectrin ELISA was per-
formed on rat thymus extracts only, since the neoepitope anti-
p120 
 
 
 
II-spectrin antibody is unreactive toward mouse-cleaved
 
 
 
II-spectrin. The anti–
 
 
 
II-spectrin neoepitope antibody was
raised against the NH
 
2
 
-terminal portion of the human caspase-3–
specific p120 fragment (immunizing peptide: NH
 
2
 
-SVEALIKC-
COOH). The assay plates were washed with Superblock/0.05%
Tween-20 buffer (Pierce Chemical Co.) between each of the fol-
lowing steps. Goat anti–rabbit–coated 96-well plates (Pierce
Chemical Co.) were incubated with 80 ng/well of anti–
 
 
 
II-spec-
trin neoepitope antibody overnight. The plates were washed, and
thymus protein lysate (200 
 
 
 
g in a final volume of 100 
 
 
 
l) was
added to each well for 1 h. The plates were washed and consecu-
tively incubated for 1 h with a 1:1,000 dilution of anti–
 
 
 
II-spec-
trin antibody (mab1622; Cedarlane), a 1:6,000 dilution of anti–
mouse biotin (Amersham Biosciences), and a 1:6,000 dilution of
streptavidin-horseradish peroxidase (Amersham Biosciences).
Color was developed with K-blue max substrate (Cedarlane) and
absorbance read at 650 nm on a Spectromax photospectrometer
(Molecular Devices). Units are expressed as OD values or as stan-
dard units from pooled thymus extracts with previously quanti-
tated p120 
 
 
 
II-spectrin.
 
Western Blotting.
 
Western blotting was performed on 40 
 
 
 
g
of heat-denatured thymic protein extract migrated through a 10–
20% acrylamide gradient SDS-PAGE Tris-Glycine gel (Invitro-
gen). The following antibodies and dilutions were used: rabbit
anti–caspase-3 antibody R280 (1:2,000 Merck-Frosst); goat anti-
murine poly(ADP-ribose) polymerase (PARP) (fragment 71–329;
1:2,000; R&D Systems); murine antispectrin (mab1622; 1:1,000;
Cedarlane); and anti–rabbit IgG-HRP (1:5,000; Amersham Bio-
sciences). Chemiluminescence was performed with Supersignal
West Femto chemiluminescent reagent (Pierce Chemical Co.)
and exposed to Hyperfilm ECL (Amersham Biosciences).
 
Flow Cytometry.
 
Phosphatidylserine exposure and propidium
iodide (PI) permeability were measured with fluorescein-labeled 
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annexin V (TACS; R&D Systems) according to the manufac-
turer’s specification and two-color flow cytometric analysis. The
presence of 
 
 
 
II-spectrin neoepitope was also determined by flow
cytometry. Rat thymocytes were fixed in PBS/0.1% sodium
azide/0.25% paraformaldehyde on ice for 1 h and permeabilized
in PBS/0.1% sodium azide/0.05% Triton X-100 for 15 min at
room temperature. After a wash step, the cells were incubated in
primary antibody solution (PBS/0.1% sodium azide, 1% normal
goat serum [NGS], 1 ng/ml anti–
 
 
 
II-spectrin neoepitope anti-
body) for 1 h. Primary antibody binding was detected using a
1:500 dilution of goat anti–rabbit IgG-Alexa 488 (Molecular
Probes) in PBS/0.1% sodium azide/1% NGS. Antibody-binding
specificity was assessed by competition with the immunizing pep-
tide. Subdiploid DNA content was determined on thymocytes
fixed for 30 min on ice in 70% EtOH. Cells were washed with
PBS and suspended in 500 
 
 
 
l of PI staining solution (PBS/0.1%
Triton X-100/RNase A [Roche]/25 
 
 
 
g/ml PI [Sigma-Aldrich]).
Flow cytometric analysis was performed on FACSCalibur (Bec-
ton Dickinson) on 20,000 events/sample, each sample prepared
in duplicates. Very small cell debris was electronically gated out
based on forward light scatter.
 
Results
 
Apoptotic Markers and Their Bcl-2 Dependency during Sepsis.
 
We first determined the contribution of necrosis and the
relevance of various apoptotic markers during sepsis by ex-
amining several indicators of cell viability in transgenic
mice that overexpress Bcl-2 in T cells. Bcl-2 is a potent an-
tiapoptotic protein that works in part by blocking cyto-
chrome-c release from mitochondria and the ensuing cas-
pase activation (17, 18). CLP was used to induce sepsis and
resulted in the appearance of the processed form of cas-
pase-3 (p17 fragment) in thymocytes from WT but not of
Bcl-2 transgenic animals. The p17 product was not detected
in sham animals regardless of their genotype (Fig. 1 A).
Hence, caspase-3 processing is induced during sepsis but
can be blocked by Bcl-2 overexpression. Next, we exam-
ined whether caspase substrates were proteolytically pro-
cessed and whether thymocytes exhibited characteristic
signs of apoptosis. The markers chosen reflect either direct
substrate cleavage (
 
 
 
II-spectrin and PARP) or the conse-
quence of caspase activation on cell function (membrane
permeability, PS exposure, and DNA fragmentation).
PARP is a nuclear enzyme that participates in DNA repair
and has been one of the first proteins identified as a caspase
substrate (19). The 24-kD NH
 
2
 
-terminal PARP cleavage
fragment was abundant in all WT mice that had undergone
CLP but was absent in most Bcl-2–overexpressing animals.
Some of the CLP-operated Bcl-2 transgenic and sham-
operated WT animals showed slight PARP 24-kD cleavage
product (Fig. 1 A). Another caspase substrate, 
 
 
 
II-spectrin,
is a major component of the cortical cytoskeleton and is
proteolytically cleaved during lymphocyte apoptosis (20).
Both calpain and caspase-3 cleave 
 
 
 
II-spectrin at multiple
sites, with the p120 fragment specifically generated upon
caspase-3 cleavage (21–23). The p120 
 
 
 
II-spectrin product
was prominent in WT mice but was absent in thymi from
septic Bcl-2 animals. No p120 fragment was observed in
sham-operated animals (Fig. 1 A). The 150-kD 
 
 
 
II-spec-
trin cleavage product, which results from both calpain and
caspase activity, was present in all animals but was more
abundant in thymi from CLP-operated mice. Thus, both
PARP and 
 
 
 
II-spectrin cleavage at the p120 site are pro-
tected from caspase cleavage in Bcl-2–overexpressing thy-
mocytes during sepsis. Bcl-2 overexpression did not affect
significantly the 
 
 
 
II-spectrin p150 cleavage site. Loss of
membrane phospholipid asymmetry and PS externalization
are detected by FITC-labeled annexin V (24). During sep-
sis, a higher proportion of thymocytes were annexin V pos-
itive in CLP relative to sham-operated WT animals (49
versus 18%, respectively, P 
 
 
 
 0.001). In contrast, the num-
ber of annexin V–positive thymocytes was virtually identi-
cal in CLP or sham animals overexpressing Bcl-2 (11.8 ver-
sus 9.3%, respectively; Fig. 1 B) but was lower than in
sham-treated WT animals. Similar results were obtained
with membrane permeability and PI uptake (Fig. 1 C). We
Figure. 1 Effect of Bcl-2 on apoptotic manifestations in the thymus of
CLP-induced septic mice. Transgenic (T cell–specific Bcl-2 overexpression)
and WT mice siblings underwent CLP or sham surgery, for a total of four
groups (WT CLP n   4; Bcl-2 CLP n   7; WT sham n   4; Bcl-2 sham
n   3). (A) Western blot from two representative animals in all four experi-
mental groups. Detection of caspase-3, PARP, and  II-spectrin cleavage
products in thymi of CLP or sham-operated mice.  , animals that carried
the bcl-2 transgene. Average percentage of annexin V–positive thymocytes
(B) and PI-permeable thymocytes (C) by flow cytometry. Average DNA
fragmentation assessed by a DNA-histone sandwich ELISA (D) or subdiploid
DNA content (E). In this figure and all subsequent figures, the error bars
represent one SD. One-way analysis of variance (ANOVA) was performed
with p-values   0.001 between CLP WT and CLP Bcl-2 groups (B–E). 
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conclude that the loss of membrane integrity and phospho-
lipid asymmetry is largely dependent on the mitochondrial
apoptotic pathway during sepsis. Cleavage of DNA at in-
ternucleosomal spaces is a well-known apoptotic marker
and is mediated by DFF40/caspase-activated DNase (CAD)
(25–27). CAD activation requires cleavage of DFF45/
inhibitor of caspase-activated DNase (ICAD) by caspases
(25–27), principally caspase-3 (23, 28–30). We measured
DNA fragmentation by the Cell Death ELISA (CDE)
method and by flow cytometry using PI staining (as de-
scribed in Materials and Methods). Thymocytes from mice
that have undergone CLP exhibited high levels of DNA
fragmentation. Overexpression of Bcl-2 in T cells abro-
gated DNA cleavage and brought the signal level to or near
values found in sham-operated animals (Fig. 1, D and E).
We conclude that DNA fragmentation, annexin V binding
and 
 
 
 
II-spectrin cleavage are dependent on the mitochon-
drial apoptotic pathway during sepsis (Table I).
 
A Caspase-3–specific Inhibitor Reduces Apoptosis during Sep-
sis.
 
Bcl-2 blocked or reduced all markers of apoptosis ex-
amined during sepsis, including caspase-3 processing itself.
It was of interest to determine if the apoptosis-specific
markers were also dependent on caspase activity in CLP-
induced sepsis. M867 is a highly potent reversible caspase
inhibitor with a fivefold preference for caspase-3 over cas-
pase-7 and little activity toward other caspases (Fig. 2 A and
 
Table I.
 
Apoptotic Markers during Experimental Peritonitis in Bcl-2 or WT Mice
 
Group
Percentage of 
subdiploid cells (
 
 
 
SE)
CDE U/mg protein 
(
 
 
 
SE)
Percentage of 
annexin V
 
 
 
 cells (
 
 
 
SE)
Percentage of 
PI-positive cells (
 
 
 
SE)
WT CLP (
 
n
 
 
 
  
 
4) 52.00 
 
  
 
2.90 246.35 
 
  
 
32.23 49.00 
 
  
 
8.07 66.12 
 
  
 
4.94
Blc-2 CLP (
 
n
 
 
 
  
 
7) 0.67 
 
  
 
0.12 9.78 
 
  
 
1.00 11.79 
 
  
 
0.96 13.98 
 
  
 
1.43
WT sham (
 
n
 
 
 
  
 
4) 0.96 
 
  
 
0.16 5.16 
 
  
 
1.47 18.44 
 
  
 
2.67 23.77 
 
  
 
5.14
Blc-2 sham (
 
n
 
 
 
  
 
3) 0.47 
 
  
 
0.09 5.66 
 
  
 
0.26 9.33 
 
  
 
0.95 10.98 
 
  
 
1.01
Figure 2. Effect of caspase-3 inhibitors on DNA frag-
mentation and  II-spectrin cleavage in the thymus of
CLP-induced septic rats. (A)  Structure of the selective
caspase-3 inhibitor M867 ((3S)-3-({(2S)-2-[5-tert-butyl-
3-{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino}-
2-oxopyrazin-1(2H)-yl]butanoyl}amino)-5-[methyl(pen-
tyl)amino]-4-oxopentanoic acid). Structures and potencies
for M826, M920, and M791 can be found in references 16
and 34. (B) Schematic representation of the experimental
design. Average  II-spectrin cleavage index (C; as described
in Materials and Methods) and DNA fragmentation (D;
percentage of subdiploid thymocytes) in CLP rats treated
with M867 (n   10) or vehicle (veh; n   10) relative to
vehicle-treated sham animals (n   3). Average  II-spectrin
cleavage index (D) and DNA fragmentation (E; percentage
of subdiploid thymocytes) in CLP rats treated with vehicle
(n   4), M867 (n   5), or inactive enantiomer compound
(M761; n   4) relative to vehicle-treated sham animals
(n   3). Statistical analysis (one-way ANOVA) indicates a
significant difference (P   0.01) between vehicle- and
M867-treated CLP rats. M867 had no effect on basal apop-
totic parameters in sham-operated animals (unpublished data). 
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Table II). We induced sepsis in rats and allowed for contin-
uous i.v. delivery of drug (Fig. 2 B). M867 infused over the
24 h after CLP reduced 
 
 
 
II-spectrin cleavage in thy-
mocytes by 88% (P   0.001) and DNA fragmentation by
57% (P   0.01; Fig. 2, C and D). To confirm that the re-
duction in apoptotic activity was specifically due to caspase
inhibition, the experiment was also performed with M761,
an inactive enantiomer of M867. Here, M867 inhibited
 II-spectrin and DNA cleavage by 88 and 60%, respec-
tively (P   0.01). In contrast, M761 could not prevent
cleavage of these two apoptotic markers (Fig. 2, E and F,
and Table III). The average M867 concentration in plasma
and spleen, with an infusion of rate 2 mg/kg/h, was 0.65  
0.18 and 0.37   0.10  M, respectively. M761 delivered
under similar conditions gave plasma and spleen drug levels
of 0.57   0.05 and 0.42   0.07  M, respectively. With
M867 and its inactive enantiomer M761 used under very
similar pharmacokinetic conditions, we conclude that
M867 specifically blocked apoptosis by inhibiting caspase-3
activity and was more effective at inhibiting substrate pro-
teolysis relative to DNA fragmentation.
 II-Spectrin and DNA Cleavage Are Not Equally Inhibited
by Caspase Inhibitors In Vitro. We were intrigued by the
fact that in our experimental model, M867 inhibited  II-
spectrin cleavage by close to 90% but reduced DNA frag-
mentation by only 60%. Several explanations can account
for this observation: (a) DNA fragmentation could be initi-
ated by a caspase other than caspase-3; (b) a DNase may be
induced by the mitochondrial apoptotic pathway (inhibited
Table II. M867 Potency against Caspases
Recombinant human caspase M867 Ki (nM)
Caspase-1 107
Caspase-2  100,000
Caspase-3 1.4
Caspase-4 495
Caspase-5 805
Caspase-6 3442
Caspase-7 8.9
Caspase-8 4032
Caspase-9 ND
Caspase-10 29490
Figure 3. Potencies of caspase-3 inhibitor M867 and ICADdm on apop-
totic manifestations in cultured thymocytes. (A) Effect of increasing
concentrations of M867 on DNA fragmentation (squares), spectrin cleavage
(circles), and annexin V labeling (triangles) in cultured rat thymocytes.
IC50s were determined by 4-parameter curve fits and are as follows: DNA
fragmentation, 0.23  M;  II-spectrin cleavage, 0.064  M; annexin V,
0.08  M. Annexin V–PI labeling (B and D) and DNA fragmentation
(C and E) in WT (B and C) and ICADdm (D and E) mouse thymocytes
cultured for 24 h. The experiment was performed with thymocytes from
three WT and three ICADdm mice. Shown here are representative results
from one animal of each genotype.
Table III. Effect of M867 on Apoptotic Markers during Experimental Peritonitis in Rat
Group Percentage of subdiploid cells ( SE) Spectrin cleavage OD ( SE)
CLP (vehicle) (n   10) 25.12   4.01 0.97   0.15
CLP (M867) (n   10) 11.61   2.95 0.30   0.01
sham (vehicle) (n   3) 1.23   0.42 0.21   0.03
CLP (vehicle) (n   4) 33.49   2.64 0.58   0.18
CLP (M867) (n   5) 13.25   4.70 0.18   0.01
CLP (M761) (n   4) 30.95   3.93 0.63   0.07
sham (vehicle) (n   3) 0.37   0.06 0.12   0.01Caspase Fractional Inhibition in Therapeutics 204
by Bcl-2) in a caspase-independent manner; or (c) a higher
fractional inhibition of caspase-3 is required to prevent the
enzymatic cascade that leads to DNA fragmentation. To
develop an in vitro cellular assay with good predictive
value as to the ability of inhibitors to block apoptosis in
sepsis, we tested the potency of several caspase inhibitors
on cultured primary rat thymocytes. These cells die sponta-
neously by apoptosis when cultured in suspension. Addi-
tionally, thymocytes are depleted during sepsis and thus
constitute relevant in vivo cellular targets. M867 (5  M)
inhibited close to 95% of both  II-spectrin cleavage and
DNA fragmentation in cultured thymocytes, establishing a
clear caspase dependency for both markers. However, the
IC50 for the reduction  II-spectrin cleavage was 64 nM,
whereas the IC50 for DNA fragmentation was 230 nM.
This discrepancy is further exemplified by the fact that 0.1
 M of M867 inhibited 60% of spectrin cleavage without
affecting DNA fragmentation (Fig. 3 A). Annexin V bind-
ing was blocked by M867 with an IC50 of 80 nM and pro-
file similar to that of  II-spectrin cleavage (Fig. 3 A). To
investigate the role of ICAD in this system, we compared
DNA fragmentation and annexin V binding in cultured
thymocytes from mice that express a caspase-resistant form
of ICAD (ICADdm; reference 31) and WT controls.
ICADdm thymocytes exhibited similar levels of spontaneous
apoptosis (annexin V staining) but showed minimal DNA
fragmentation (2 versus 42% subdiploid population for WT
thymocytes; Fig. 3, B–E). Thus, cleavage of ICAD is re-
quired for DNA fragmentation and accounts for the vast
majority of the activity. To evaluate whether caspases other
than caspase-3 could be affecting DNA cleavage, broad
specificity caspase inhibitors (M920, zVAD-fluoromethyl
ketone [fmk], M808, and M310) or a strictly caspase-3–
specific inhibitor (M791) were tested (Table IV). All broad
range inhibitors exhibited an even greater potency shift be-
tween  II-spectrin and DNA cleavage, whereas M791 was
shifted fourfold, similarly to M867. Thus, it seems unlikely
that residual DNA fragmentation activity is due to a caspase
that is blocked by none of the inhibitors used. Together,
the results demonstrate that, in general, a higher dose of
caspase inhibitor is required to block DNA fragmentation
compared with the inhibition of other apoptotic markers.
Potency Shift of Caspase Inhibitors In Vivo during Experimen-
tal Peritonitis. DNA fragmentation in cultured thymocytes
is almost completely caspase-3 and ICAD dependent.
Given the shift in potency that was observed between  II-
Figure 4. Effect of M867 dose titration on caspase-3 cleavage,  II-
spectrin cleavage, and DNA fragmentation in CLP-induced septic rats.
Rats that underwent CLP surgery were dosed by continuous i.v. infusion
of either vehicle (n   6) or M867 (n   1 for each dose) for 24 h. (A) Per-
centage of residual  II-spectrin cleavage (circles) and DNA fragmentation
(triangles) in each animal after administration of various doses of M867.
Percentages were calculated from the average  II-spectrin and DNA frag-
mentation values obtained with the vehicle-treated animals. (B) Caspase-3
Western blotting on thymus extracts of animals dosed with M867.
Table IV. Comparative Potencies of Various Caspase Inhibitors Using  II-Spectrin Cleavage and DNA Fragmentation as Activity Readout
Inhibitor Type IC50 spectrin IC50 subdiploid Potency shift
 M  M
M791 C3 specific 1.16 4.90 4
M826 C3 preference 0.04 0.13 3
M867 C3 preference 0.07 0.27 4
M920 Poly 0.25 4.90 19
M808 Poly 0.30 2.41 8
M310 Poly 0.01 0.33 23
zVAD-fmk Poly 0.60 25.00 42
Average of two to four experiments for M791, M826, M867, M920, and M310. Single experiment for zVAD-fmk and M808. C3 refers to caspase-3.Méthot et al. 205
spectrin and DNA cleavage in vitro, we asked whether a
similar shift would be present in vivo during CLP-induced
thymocyte apoptosis. To that end, a dose–response curve
for  II-spectrin cleavage and DNA fragmentation was per-
formed in septic rats, at M867 doses ranging from 0 to 10
mg/kg/h. M867 reduced  II-spectrin cleavage in a dose-
dependent manner, with 50% inhibition at  0.5 mg/kg/h
and an almost complete inhibition at 2 mg/kg/h (Fig. 4 A).
Inhibition of DNA fragmentation was dose dependent but
required larger amounts of drug (50% inhibition at  2 mg/
kg/h; Fig. 4 A). Importantly, DNA fragmentation was al-
most abrogated by M867, indicating caspase-3 (and possi-
bly caspase-7) dependency in this model. At all M867
doses, caspase-3 was processed equally well, evidence that
this inhibitor did not prevent upstream events leading to
caspase-3 activation (Fig. 4 B). Hence, the process of DNA
fragmentation during experimental peritonitis is largely cas-
pase-3 dependent. As is the case with cultured thymocytes,
drug levels must be fourfold higher to inhibit DNA cleav-
age compared with  II-spectrin cleavage.
Discussion
The development of efficacious therapeutics requires a
good understanding of the target and its site of action in
animal models mimicking the human disease. CLP in rats
and mice is an accepted sepsis animal model with demon-
strated apoptosis and caspase contributions. Studies with
genetic and pharmacological inhibitors of apoptosis in sep-
sis animal models suggest that caspase inhibition may im-
prove septic patient survival (10–16).
We have made use of transgenic mice that overexpress
Bcl-2 in T cells to evaluate the apoptotic component of
various commonly used cell death markers in septic mice.
We found that  II-spectrin cleavage at the p120 caspase
site and DNA fragmentation are two markers with an al-
most absolute dependency on the mitochondrial apoptotic
pathway. Annexin V binding, PI permeability, and PARP
cleavage were also strongly associated with CLP-induced
apoptosis. However, residual signal even in the presence of
Bcl-2 suggests a partial nonmitochondrial contribution
(Fig. 1). We also compared Bcl-2 and WT sibling septic
mice to identify markers that may predict survival. Al-
though Bcl-2 transgenic mice showed on average slightly
more white blood cells and lymphocytes than their WT
counterparts, the difference was not statistically significant
(unpublished data). No difference in blood chemistry (glu-
cose, urea, AST, ALT) was noted between the two groups
(unpublished data).
As with Bcl-2, the caspase-3–specific inhibitor M867 re-
duced  II-spectrin cleavage and DNA fragmentation dur-
ing CLP-induced sepsis in rats. Strikingly, whereas Bcl-2
abrogated the appearance of both markers, M867 showed a
markedly different efficacy at blocking  II-spectrin cleav-
age relative to DNA fragmentation in vitro and in animals
(Figs. 2 and 3). We systematically examined several possi-
bilities that may account for this observation. In cultured
rat thymocytes, virtually all DNA fragmentation was
blocked by high doses of M867 (5  M), indicating an ab-
solute caspase dependency. An uncleavable form of ICAD
also abrogated DNA fragmentation in this system. Thus,
the reduced ability of M867 at blocking DNA fragmenta-
tion is neither caused by a noncaspase or an ICAD-inde-
pendent DNase. Furthermore, several polycaspase inhibi-
tors exhibited a strong potency shift, making it unlikely
that a caspase other than caspase-3 (or in some instances
caspase-7) cleave ICAD. This phenomenon was not re-
stricted to rat thymocytes, since camptothecin-treated Jur-
kat cells also exhibited IC50 potency shifts between  II-
spectrin and DNA cleavage with several caspase inhibitors
(unpublished data).
The need for higher levels of caspase inhibitor to prevent
apoptosis-induced DNA fragmentation was observed in
vivo with septic rats dosed with M867. Abolition of  II-
spectrin cleavage was achieved with doses below 2 mg/
kg/h, and DNA fragmentation was fully inhibited with doses
above 5 mg/kg/h. A crude extrapolation of the in vivo
IC50 values for M867 would place  II-spectrin cleavage at
0.5 mg/kg/h and DNA fragmentation at 2 mg/kg/h (Fig.
4), a potency shift similar to that observed on cultured rat
thymocytes. M867 blood levels in animals dosed with 0.5
and 1.5 mg/kg/h were 0.14 and 0.70  M, respectively,
which roughly corresponds to  II-spectrin and DNA
cleavage IC50s measured in cultured rat thymocytes. The
exact biochemical cause for the IC50 shift is not known. It
is possible that ICAD, whose caspase-mediated cleavage is
required to initiate DNA fragmentation (25–27) is a better
caspase-3 substrate than the p120 site of  II-spectrin. Alter-
natively, since at least one enzymatic amplification step sep-
arates caspase-mediated ICAD cleavage from CAD-medi-
ated DNA fragmentation, a small amount of ICAD
cleavage may result in some CAD release and a dispropor-
tionately larger amount of DNA fragmentation. The steep-
ness of the caspase inhibitor titration curves agrees with this
possibility (Fig. 3 A). The amount of  II-spectrin cleavage
activity changes from 100 to 5% over two logarithmic units
of M867 concentration. In contrast, a similar change in
DNA fragmentation activity takes place in only one loga-
rithmic unit, indicating the presence of a threshold effect.
A higher fractional inhibition of caspase activity may be re-
quired to pass this threshold. Alternatively, a difficulty for
some caspase inhibitors at accessing the nucleus where
some of the CAD–ICAD complex reside (32, 33) may
leave nuclear caspase-3 partially unblocked. We are cur-
rently investigating these possibilities. In summary, our
work illustrates the need to gage DNA fragmentation as an
indication of success at blocking apoptosis and suggests that
in acute apoptotic pathologies high and persistent levels of
caspase inhibition will be needed clinically. Based on our
study of potency shifts, we suggest that a caspase-3–specific
reversible inhibitor would represent a potential therapeutic
approach in acute apoptotic diseases such as sepsis. Finally,
given the high degree of fractional inhibition of caspases re-
quired to block apoptosis low potency caspase inhibitorsCaspase Fractional Inhibition in Therapeutics 206
(such as z-VAD-fmk) cannot be used as criteria for estab-
lishing caspase-independent cell death events.
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analysis and discussions on experimental design.
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